Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 11Neoplasms 5Stomach Neoplasms 3Pain, Postoperative 2Pain 2Motor Activity 2Lung Neoplasms 2Head and Neck Neoplasms 2Fatigue 2Colonic Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma 1Psychological Well-Being 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Lymphoma 1Lymphedema 1Lymphatic Metastasis 1Locally Advanced Head and Neck Squamous Cell Carcinoma 1Leukemia, Myeloid, Acute 1Leukemia 1Incisional Hernia 1Hernia, Abdominal 1Heart Failure 1Esophageal Neoplasms 1Endometrial Neoplasms 1Diarrhea 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Ivabradine 2Watchful Waiting 1Standard of Care 1Spironolactone 1Secondary Prevention 1Population Groups 1Perindopril 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Exercise 1Control Groups 1Blood Specimen Collection 1Bisoprolol 1Atorvastatin 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Heart Failure × Control Groups × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡